Agilent Technologies has agreed to acquire digital pathology software provider Proscia for $240 million in cash plus up to $30 million in earnouts. Proscia generates over $18 million in revenue serving 4,000 health institutions and 16 top pharma companies. The deal enhances Agilent's AI-enabled diagnostic capabilities and companion diagnostics portfolio, expanding its foothold in the $5 billion pathology market upon closing in early fiscal year 2027.
Acquisition terms and timeline
- ▪Agilent Technologies entered into a definitive agreement to acquire digital pathology software provider Proscia on October 13, 2026.
- ▪The acquisition agreement includes up to an additional $30 million in cash payments to Proscia based on achieving future performance milestones.
- ▪Agilent Technologies agreed to acquire Proscia in an all-cash transaction valued at $240 million at closing.
- ▪The acquisition of Proscia is expected to close early in Agilent Technologies' fiscal year 2027, subject to customary closing conditions.
Strategic context and integration
- ▪Agilent Technologies' purchase of Proscia follows the completion of Agilent's transaction with Biocare Medical to expand its pathology portfolio.
- ▪Upon closing of the acquisition, Proscia will become part of the Agilent Life Sciences and Diagnostics Markets Group.
- ▪The acquisition builds on a multi-year distribution agreement entered into by Agilent Technologies and Proscia in September 2022.
Strategic rationale and AI synergies
- ▪The acquisition of Proscia establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation.
- ▪The acquisition of Proscia is intended to offer AI-enabled synergies with Agilent Technologies' companion diagnostics business in drug discovery and clinical research.
Proscia software capabilities
- ▪Proscia's software converts physical pathology slides into digital images that can be stored, reviewed, and analyzed using artificial intelligence tools.
- ▪Proscia's software platform connects slide scanners, laboratory information systems, image-analysis applications, and artificial intelligence tools into a unified operating layer.
- ▪Proscia's digital pathology software platform holds FDA 510(k) clearance for primary diagnosis.
Proscia commercial scale and reach
- ▪Proscia's digital pathology platform serves as a key software layer targeting the broader $5 billion pathology market.
- ▪Proscia generated trailing twelve months revenue exceeding $18 million prior to the acquisition agreement with Agilent Technologies.
- ▪Proscia serves more than 4,000 laboratories, hospitals, and clinics, as well as 16 of the top 20 pharmaceutical companies across the U.S. and Europe.
Debatable claims
- ▪AI software is reliable enough for primary clinical pathology diagnosis
- ▪Diagnostic equipment manufacturers should not acquire independent pathology software platforms
Story comments
Loading comments…